Blog: No Easy Cure For Britain’s Brexit Madness
Prime Minister Boris Johnson has until 19 October to agree a deal, or otherwise must ask for another Brexit extension. But he's in no mood to follow the rules.
You may also be interested in...
The UK BioIndustry Association has warned that a wide range of life sciences companies, including small and medium sized firms, are still not fully aware of what a no-deal Brexit might mean for them.
The UK’s main opposition party says it would use compulsory licensing to ensure access to “extortionately” priced medicines. Unsurprisingly, the responses are polarized.
The UK government will consider all options to improve access to Vertex’s cystic fibrosis treatment, including compulsory licensing.